# Hantavirus Pulmonary Syndrome in a COVID-19 Patient, Argentina, 2020

## Appendix

**Appendix Table.** Clinical and virologic laboratory findings*

| Characteristic | Reference value | Days after onset of symptoms | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | 3 | 5 | 6 | 7 | 9 | 10 | 12 | 13 | 14 | 16 | 18 |
| Platelet count, cell/mm$^3$ | 154–383 | ND | 55 | 50 | 73 | 100 | 136 | ND | 200 | ND | 332 | ND |
| Hemoglobin, g/dL | 11.8–15.5 | ND | 18.3 | 16.9 | 13 | 8.5 | 9.6 | ND | 8.2 | ND | 8.6 | ND |
| Total leukocytes, 10$^3$μL | 4.1–9.8 | ND | 17.2 | 12.8 | 12.3 | ND | 10.8 | ND | 12.3 | ND | ND | ND |
| Monocytes, % | 5.1–10.1 | ND | ND | 2 | ND | ND | 14.3 | ND | 14 | ND | ND | ND |
| Lymphocyte, % | 19.4–44.1 | ND | ND | 9 | ND | ND | 23.3 | ND | 24 | ND | ND | ND |
| Neutrophils, % | 41–73.1 | ND | ND | 58 | ND | ND | 56.1 | ND | 60 | ND | ND | ND |
| NLR, % | 1–3† | ND | ND | 6.4 | ND | ND | 2.4 | ND | 2.5 | ND | ND | ND |
| AST, UI/L | 0–32 | ND | ND | 107 | 70 | 95 | 90 | 68 | ND | 46 | ND | ND |
| ALT, UI/L | 0–31 | ND | ND | 38 | 28 | 56 | 63 | 79 | ND | 58 | ND | ND |
| SARS CoV-2 | | | | | | | | | | | | |
|   RT-PCR gene ORF 1 AB | $C_t$ >38 | 34.07 | ND | ND | ND | ND | 35.02 | ND | ND | ND | ND | Negative |
|   RT-PCR gene N | $C_t$ >38 | 29.92 | ND | ND | ND | ND | 32.05 | ND | ND | ND | ND | Negative |
| Hantavirus | | | | | | | | | | | | |
|   ELISA IgM | Cut off 0.3 | ND | ND | ND | ND | ND | 1.64 | ND | ND | ND | ND | 2.80 |
|   ELISA IgG | Cut off 0.55 | ND | ND | ND | ND | ND | 2.8 | ND | ND | ND | ND | 3.39 |
|   RT-PCR | $C_t$ >38 | ND | ND | ND | ND | ND | 24.4 | ND | ND | ND | ND | ND |

*ALT alanine aminotransferase; AST, aspartate aminotransferase, $C_t$, cycle threshold; ND, not done; RT-PCR, reverse transcription PCR, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
†PulmCrit.